BACKGROUND: @entity63 reperfusion causes injury to the liver cells during transplantation, @entity130 and emergency surgery. We investigated whether the anti @entity310 agent, etanercept, can reduce injury in an animal model of @entity63 reperfusion owing to the fact that @entity310 plays a critical role in the process of @entity32 . MATERIALS AND METHODS: Thirty @entity35 were divided into three groups: sham (Group 1), control (Group 2), etanercept (5 mg/kg) treatment (Group 3). @entity63 -reperfusion model was carried out by clamping the hepatic pedicle for 45 min and then reperfusing the liver for 60 min. Etanercept (5 mg/kg) was injected intraperitoneally 5 min prior to reperfusion. At the end of the procedures, blood and liver tissue samples were obtained for biochemical and histopathological assessment. RESULTS: Control and treatment groups showed significant differences in hepatic function tests, plasma and tissue oxidative stress parameters. Samples in the control group histopathologically showed @entity154 specific to @entity63 reperfusion. Histomorphologic findings in the treatment groups showed similar features as the sham group. CONCLUSIONS: Our evidence suggests that @entity310 plays a key role in @entity409 reperfusion injury and etanercept may provide a novel therapeutic approach for @entity1 undergoing liver surgical procedure (Tab. 3, Fig. 4, Ref. 22).

Ultrastructural view of a promising anti XXXX agent on hepatic ischaemia reperfusion injury.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity154 :: ('MESH:D000013', 'Disease') :: ['morphologic abnormalities'] @entity63 :: ('MESH:D007511', 'Disease') :: ['Ischemia', 'ischemia'] @entity310 :: ('7124', 'Gene') :: ['TNF-a'] @entity409 :: ('MESH:D008107', 'Disease') :: ['liver ischemia'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity130 :: ('MESH:D014947', 'Disease') :: ['trauma']
@entity310 :: (7124,Gene) :: ['TNF-a']
